Article By:
The Fly
Friday, December 27, 2019 11:16 AM EDT
Benchmark analyst Bruce Jackson raised his price target for Flexion Therapeutics to $25 from $19 after the company received FDA approval to update the product label for Zilretta for the treatment of osteoarthritis knee pain.
In this article: FLXN
Whither Flexion?
Sounds like it's time to short! $FLXN
Whither Flexion?
So $FLXN is essentially a one trick pony? Didn't realize Zilretta was so critical to the companies existence. Do you know what percentage of its profits are tied to this one therapy?